Additional European Equity News - 19th November 2026
ORIGINAL · NewsquawkAdditional European Equity News - 19th November 2026Read originalHide original
Air Liquide (AI FP) - UK CMA is investigating the anticipated acquisition by Vivisol of Air Liquide Healthcare Limited’s home oxygen services business, warning that Vivisol's proposed acquisition of Air Liquide's home oxygen healthcare unit could harm competition in the UK market. (UK CMA) AstraZeneca (AZN LN) - Co. says Sonesitatug vedotin has been granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers. (AstraZeneca) Babcock (BAB LN) - H1 2027 (GBP): Revenue 2.70bln (exp. 2.64bln, prev. 2.54bln Y/Y), Operating Profit 220.7mln (prev. 234.3mln Y/Y), Pretax Profit 216.2mln (exp. 205.9mln), Net Income 159.8mln (exp. 156.6mln). Raises its dividend to 2.8p/shr. Backs its FY27 view and medium-term guidance. Says around 90% of its expected FY27 revenue was under contract at October 1st. (Babcock) Commerzbank (CBK GY), UniCredit (UCG IM) - Commerzbank confirms the agreement between Germany and UniCredit regarding the takeover. Commerzbank says that it will remain on the stock exchange. (Commerzbank) Defence Names - The Dutch government is reportedly planning a EUR 1.6bln defence programme over the next six years. (Newswires) GSK (GSK LN) - Co. announces that velzatinib has received Orphan Drug Designation from Japan’s Ministry of Health Labour and Welfare for the treatment of gastrointestinal stromal tumour. (GSK) Halma (HLMA LN) - H1 2027 (GBP): Revenue 1.43bln (prev. 1.24bln Y/Y), Adj. EBIT 345.4mln (prev. 282mln Y/Y). Reaffirms FY27 guidance for low double-digit organic constant currency revenue growth, including a c. 5ppts contribution from its photonics business. Expects adjusted EBIT margin of 23.5-24%. Notes a strong start to H2 despite varied end-market conditions and elevated economic and geopolitical uncertainty. (Halma) Investec (INVP LN) - H1 2027 (GBP): Revenue 1.17bln (prev. 1.10bln Y/Y), Adj. Operating Profit 494.5mln (prev. 468.1mln), Adj. EPS 0.435 (prev. 0.405 Y/Y), NAV/Shr 6.56 (prev. 6.08 Y/Y). Says growth strategy remains on track, with investment in strategic initiatives expected to peak in the current financial year and support improving earnings growth and ROE from FY28. Reaffirms FY28 ROE guidance of 13.8-14.6% and ROTE guidance of 15.8-16.6%. (Investec) JD Sports Fashion (JD/ LN) - Q3 Trading Update: Group Comparable Sales -1.8% Y/Y, LFL Revenue -2.6% Y/Y, Organic Sales -1.1%, with sales trends improving from Q2. Narrows FY27 pretax profit guidance to GBP 700-750mln (prev. guided 700-800mln, exp. 723mln) and maintains FCF guidance at GBP 460-520mln (exp. 486mln). Says it is rapidly expanding the use of AI across its business, including customer discovery and inventory management. Unseasonably warm weather delayed the Autumn and Winter demand while footwear remained soft. (JD Sports Fashion) L'Oréal (OR FP), EssilorLuxottica (EL FP) - L'Oréal is reportedly set to lead an investor consortium seeking to acquire a combined 15% stake in Armani, with L'Oréal targeting c. 10% and EssilorLuxottica considering a stake of up to 5%, according to Corriere della Sera citing sources. (Corriere della Sera) Sage (SGE LN) - FY 2026 (GBP): ARR 2.88bln (prev. 2.59bln Y/Y), Revenue 2.78bln (prev. 2.51bln Y/Y), Operating Profit 681mln (exp. 678mln, prev. 601mln Y/Y). Expects FY27 organic total revenue growth of c. 10%, with underlying operating margins anticipated to continue improving as the Group focuses on scaling its operations efficiently. Says it enters FY27 with strong momentum. (Sage) Subsea 7 (SUBC NO) - Q3 2026 (USD): Revenue 2.07bln (exp. 1.99bln), Adj. EBITDA 549mln (exp. 502.8mln). Guides FY26 Revenue at 8bln (exp. 7.75bln). (Subsea 7) Swiss Watch Names - Swiss Watch Exports 9.1% Y/Y (prev. 11.7%). 3I (III LN) initiated with Market Perform at Keefe Bruyette CVC (CVC NA) initiated with Outperform at Keefe Bruyette EQT (EQT SS) initiated with Market Perform at Keefe Bruyette ICG (ICG LN) initiated with Outperform at Keefe Bruyette Partners Group (PGHN SW) initiated with Underperform at Keefe Bruyette
European companies reported a mix of stronger-than-expected results and narrower outlooks, with JD Sports also having completed a share buyback tranche ahead of schedule.
News detail
Air Liquide (AI FP) - UK CMA is investigating the anticipated acquisition by Vivisol of Air Liquide Healthcare Limited’s home oxygen services business, warning that Vivisol's proposed acquisition of Air Liquide's home oxygen healthcare unit could harm competition in the UK market. (UK CMA) AstraZeneca (AZN LN) - Co. says Sonesitatug vedotin has been granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers. (AstraZeneca) Babcock (BAB LN) - H1 2027 (GBP): Revenue 2.70bln (exp. 2.64bln, prev. 2.54bln Y/Y), Operating Profit 220.7mln (prev. 234.3mln Y/Y), Pretax Profit 216.2mln (exp. 205.9mln), Net Income 159.8mln (exp. 156.6mln). Raises its dividend to 2.8p/shr. Backs its FY27 view and medium-term guidance. Says around 90% of its expected FY27 revenue was under contract at October 1st. (Babcock) Commerzbank (CBK GY), UniCredit (UCG IM) - Commerzbank confirms the agreement between Germany and UniCredit regarding the takeover. Commerzbank says that it will remain on the stock exchange. (Commerzbank) Defence Names - The Dutch government is reportedly planning a EUR 1.6bln defence programme over the next six years. (Newswires) GSK (GSK LN) - Co. announces that velzatinib has received Orphan Drug Designation from Japan’s Ministry of Health Labour and Welfare for the treatment of gastrointestinal stromal tumour. (GSK) Halma (HLMA LN) - H1 2027 (GBP): Revenue 1.43bln (prev. 1.24bln Y/Y), Adj. EBIT 345.4mln (prev. 282mln Y/Y). Reaffirms FY27 guidance for low double-digit organic constant currency revenue growth, including a c. 5ppts contribution from its photonics business. Expects adjusted EBIT margin of 23.5-24%. Notes a strong start to H2 despite varied end-market conditions and elevated economic and geopolitical uncertainty. (Halma) Investec (INVP LN) - H1 2027 (GBP): Revenue 1.17bln (prev. 1.10bln Y/Y), Adj. Operating Profit 494.5mln (prev. 468.1mln), Adj. EPS 0.435 (prev. 0.405 Y/Y), NAV/Shr 6.56 (prev. 6.08 Y/Y). Says growth strategy remains on track, with investment in strategic initiatives expected to peak in the current financial year and support improving earnings growth and ROE from FY28. Reaffirms FY28 ROE guidance of 13.8-14.6% and ROTE guidance of 15.8-16.6%. (Investec) JD Sports Fashion (JD/ LN) - Q3 Trading Update: Group Comparable Sales -1.8% Y/Y, LFL Revenue -2.6% Y/Y, Organic Sales -1.1%, with sales trends improving from Q2. Narrows FY27 pretax profit guidance to GBP 700-750mln (prev. guided 700-800mln, exp. 723mln) and maintains FCF guidance at GBP 460-520mln (exp. 486mln). Says it is rapidly expanding the use of AI across its business, including customer discovery and inventory management. Unseasonably warm weather delayed the Autumn and Winter demand while footwear remained soft. (JD Sports Fashion) L'Oréal (OR FP), EssilorLuxottica (EL FP) - L'Oréal is reportedly set to lead an investor consortium seeking to acquire a combined 15% stake in Armani, with L'Oréal targeting c. 10% and EssilorLuxottica considering a stake of up to 5%, according to Corriere della Sera citing sources. (Corriere della Sera) Sage (SGE LN) - FY 2026 (GBP): ARR 2.88bln (prev. 2.59bln Y/Y), Revenue 2.78bln (prev. 2.51bln Y/Y), Operating Profit 681mln (exp. 678mln, prev. 601mln Y/Y). Expects FY27 organic total revenue growth of c. 10%, with underlying operating margins anticipated to continue improving as the Group focuses on scaling its operations efficiently. Says it enters FY27 with strong momentum. (Sage) Subsea 7 (SUBC NO) - Q3 2026 (USD): Revenue 2.07bln (exp. 1.99bln), Adj. EBITDA 549mln (exp. 502.8mln). Guides FY26 Revenue at 8bln (exp. 7.75bln). (Subsea 7) Swiss Watch Names - Swiss Watch Exports 9.1% Y/Y (prev. 11.7%). 3I (III LN) initiated with Market Perform at Keefe Bruyette CVC (CVC NA) initiated with Outperform at Keefe Bruyette EQT (EQT SS) initiated with Market Perform at Keefe Bruyette ICG (ICG LN) initiated with Outperform at Keefe Bruyette Partners Group (PGHN SW) initiated with Underperform at Keefe Bruyette
Related stocks
3 stocksWhat do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
